New AI Model Maps How Different Areas of a Tumor Respond to Cancer Drugs
Researchers have developed DeepTNR, a deep-learning framework that uses spatial transcriptomics to predict drug sensitivity across the diverse microenvironments of a tumor.
Key points
- DeepTNR uses spatial transcriptomics to predict drug responses based on cell location within a tumor.
- The model identified irinotecan as a highly sensitive treatment option in colorectal cancer simulations.
- Spatial proximity to immune-rich areas was linked to increased drug effectiveness in the study's findings.
Researchers from the Chengdu University of Traditional Chinese Medicine have developed a new computational framework called DeepTNR, designed to predict how different regions within a single tumor might respond to specific medications. Published in npj Digital Medicine, the study addresses the challenge of intratumoral heterogeneity—the phenomenon where various parts of a tumor exhibit different genetic and physical characteristics, often leading to inconsistent treatment results.
Mapping Spatial Sensitivity
Unlike traditional drug-sensitivity models that analyze a tumor as a single bulk mass, DeepTNR utilizes spatial transcriptomics. This allows the AI to account for the physical organization of cells and the interface between the tumor and its surrounding stroma. By integrating spatial autocorrelation and distance-dependent associations, the model can identify "niche-specific vulnerabilities" that might be missed by standard diagnostic tools.
Findings in Colorectal Cancer
The research team tested the framework across nine different tumor types. Using colorectal cancer as a primary example, DeepTNR identified the chemotherapy drug irinotecan as having the highest predicted sensitivity. The model further revealed that areas with high concentrations of immune and proliferative cellular programs were more likely to respond positively to the drug. This suggests that the local environment of a cell significantly dictates its vulnerability to treatment.
What to know: This research introduces a digital tool for precision oncology, though it remains in the computational validation stage. Patients should always consult with their oncology team regarding specific treatment plans and drug sensitivities.
Source Nature Health Sciences — nature.com/articles/s41746-026-03459-8 ↗
Read next
🧠Mind & Mental HealthStudy Finds Mixed Clinical Alignment in Reddit Mental Health Advice
A new Flinders University study reveals that while popular peer advice on Reddit often recommends professional help for depression and anxiety, some responses lack the ne…
❤️Conditions & CarePapua New Guinean Tree Compound Shows Potential in Motor Neuron Disease Study
Researchers at the University of Wollongong identified a natural compound from a rainforest tree that protected motor neurons against degeneration in laboratory tests.
🏥Public HealthNew Parents with Intellectual Disabilities Face Significantly Higher Rates of Psychiatric Hospitalizations
Recent Australian research reveals that new parents with intellectual disabilities experience drastically elevated rates of emergency room visits and hospital admissions …
🔬ResearchEarly Sleep-Focused Telehealth Therapy May Help Trauma Survivors Access Mental Health Care
Initial findings from the RESTED clinical trial at Henry Ford Health indicate that providing early telehealth therapy for nightmares following trauma significantly increa…
🔬ResearchFDA Issues Safety Warning Linking GLP-1 Medications to Rare Eye Condition
The U.S. Food and Drug Administration has issued a safety communication warning of a potential link between GLP-1 receptor agonists and a rare, permanent vision condition…
🏃FitnessExploring Longevity Fitness Competitions: What Testing Healthspan Markers Means for Workout Routines
A new live longevity fitness competition called the Super Age Games tests participants on eight markers linked to healthspan, offering a glimpse into how physical perform…